Clinical Trials on Thrombosis, Venous in Japan

Total 136 results

Medical University of South Carolina

Recruiting

Stroke Thrombectomy and Aneurysm Registry (STAR)

Stroke | Thromboses, Intracranial | Aneurysm, Brain

United States, Spain, Korea, Republic of, Germany, Switzerland, Canada, Argentina, Japan, Portugal, Uruguay, Egypt
National Cerebral and Cardiovascular Center
Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan

Completed

Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke Patients

Stroke | Cerebral Embolism

Japan
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (COMINO)

Central Retinal Vein Occlusion | Macular Edema | Hemiretinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Germany, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Bayer
Janssen Research & Development, LLC

Completed

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEIN Jr)

Venous Thromboembolism

Belgium, China, Hong Kong, United States, Switzerland, Spain, Russian Federation, Singapore, Canada, Germany, Netherlands, United Kingdom, Austria, Brazil, Israel, Italy, Mexico, Turkey, France, Australia, Finland, Hungary, Japan, Arg... and more
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN)

Central Retinal Vein Occlusion

China, Czechia, Germany, Russian Federation, Turkey, United States, Australia, Canada, Spain, United Kingdom, Thailand, Israel, Netherlands, Italy, Hungary, France, Greece, Puerto Rico, Malaysia, Japan
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)

Branch Retinal Vein Occlusion

China, Austria, Czechia, Russian Federation, Taiwan, United Kingdom, Canada, Japan, United States, France, Israel, Germany, Italy, Hong Kong, Spain, Denmark, Slovakia, Puerto Rico, Switzerland
Japan Community Health Care Organization Sendai...

Unknown

Clinical Study to Evaluate the Efficacy of Blood Purification Therapy on Cholesterol Crystal Embolism

Cholesterol Embolism

Japan
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients (MAGELLAN)

Venous Thromboembolism

Belgium, France, Norway, Spain, China, Taiwan, United States, Switzerland, Colombia, Canada, Estonia, New Zealand, Finland, Italy, Portugal, Japan, Singapore, Germany, Greece, Australia, Sweden, Austria, Chile, Slovakia, United Kingdom, M... and more
Bayer
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Macular Edema Secondary to Retinal Vein Occlusion

Korea, Republic of, Japan, China, Lithuania, United States, Italy, Spain, Hungary, Israel, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Germany, Latvia, Mal... and more
Surugadai Nihon University Hospital
Teikyo University

Completed

Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Chronic Central Serous Chorioretinopathy

Japan
Tohoku University

Unknown

Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation (EXPAND)

Non-valvular Atrial Fibrillation

Japan
Shinichi Yoshimura

Terminated

Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan RCT

Ischemic Stroke

Japan
Hyogo College of Medicine

Completed

Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan Registry 2

Ischemic Stroke

Japan
Yokohama City University Medical Center
Teikyo University

Completed

Assessment of Distal Protection Device in Patients at High Risk for Distal Embolism in Acute Coronary Syndrome (ACS) (VAMPIRE3)

Coronary Artery Disease

Japan
Eisai Inc.
Eisai Co., Ltd.

Completed

Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism

Pulmonary Embolism

Japan
Japan Cardiovascular Research Foundation

Unknown

RELAXED: Recurrent Embolism Lessened by Rivaroxaban for Acute Ischemic Stroke (RELAXED)

Atrial Fibrillation | Stroke, Acute

Japan
Novartis Pharmaceuticals

Completed

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS)

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Age Related Macular Degeneration | Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion

Spain, China, Colombia, Korea, Republic of, Belgium, Greece, Japan, Russian Federation, Turkey, United Kingdom, Egypt, Germany, Australia, Canada, France, Austria, Hong Kong, Hungary, Israel, Netherlands, Peru, Singapore, Slovakia, Sl... and more
Abbott Medical Devices

Completed

XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan

Myocardial Ischemia | Coronary Artery Disease | Coronary Disease | Stent Thrombosis | Coronary Restenosis | Chronic Coronary Occlusion | Vascular Disease | Coronary Artery Stenosis | Angina

Japan
Astellas Pharma Inc

Completed

A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients

Bone Marrow Transplantation | Graft Versus Host Disease | Graft-Versus-Host Disease | Graft-Vs-Host Disease

Japan
Janssen Research & Development, LLC
Bayer

Completed

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure (UNIVERSE)

Thrombosis

United States, Spain, Argentina, Malaysia, Japan, Belgium, Canada, Netherlands, Brazil, Mexico
Insel Gruppe AG, University Hospital Bern
Swiss National Science Foundation; Mach Gaensslen Foundation; Baxalta Innovations...

Recruiting

Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome) (TTP registry)

Thrombotic Thrombocytopenic Purpura | Congenital Thrombotic Thrombocytopenic Purpura | Familial Thrombotic Thrombocytopenic Purpura | Thrombotic Thrombocytopenic Purpura, Congenital | Upshaw-Schulman Syndrome

United States, Austria, Czechia, Germany, Japan, Norway, Switzerland
Astellas Pharma Inc

Completed

A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-

Bone Marrow Transplantation | Graft Versus Host Disease | Graft-Versus-Host Disease | Graft-Vs-Host Disease

Japan
Sanofi

Completed

A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Thrombotic Thrombocytopenic Purpura

Japan
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Thrombosis

United States, Japan
Baxalta now part of Shire

Completed

Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

United States, Germany, United Kingdom, Switzerland, Austria, Japan, Poland
Kissei Pharmaceutical Co., Ltd.

Completed

A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788

Idiopathic Thrombocytopenic Purpura

Japan
MiMedx Group, Inc.
CMIC Co, Ltd. Japan

Recruiting

Post-Marketing Surveillance of Dehydrated Human Amnion/Chorion Membrane (DHACM) in Non-Ischemic Chronic Wounds

Diabetic Foot Ulcer | Venous Leg Ulcer

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

Graft vs Host Disease

Japan
Alexion Pharmaceuticals

Completed

The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

Japan
Alexion Pharmaceuticals

Completed

To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients

ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

Japan
GlaxoSmithKline

Completed

The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

Embolism, Pulmonary

Japan
GlaxoSmithKline

Completed

Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopenic, Idiopathic | Idiopathic Thrombocytopenic Purpura

Japan
Takeda
Shire; Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura (TTP)

China, United States, France, Japan, Poland, Germany, Austria, Spain, Italy, Switzerland, United Kingdom
Takeda

Completed

Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"

Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other

Japan
GlaxoSmithKline

Completed

Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic

Japan
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Completed

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States, Spain, Germany, Italy, Poland, Japan, Austria, United Kingdom, France
Novartis Pharmaceuticals

Completed

Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease

Acute Graft Versus Host Disease

Belgium, Japan, Spain, France, Korea, Republic of, Canada, Italy, Denmark
Incyte Corporation

Completed

Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects

Acute Graft-versus-host Disease

Japan
Boston Scientific Corporation

Active, not recruiting

Intra-operative Pancreatoscopy in Patients With IPMN

Intraductal Papillary Mucinous Neoplasm

United States, Netherlands, China, India, Japan, Sweden
Bayer
Janssen Research & Development, LLC

Completed

Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

Pulmonary Embolism

Japan
Alexion Pharmaceuticals, Inc.

Recruiting

Study of Ravulizumab in Pediatric Participants With HSCT-TMA

Thrombotic Microangiopathy

United States, France, Israel, Italy, Japan, Korea, Republic of, Spain, United Kingdom, Germany
Amgen

Terminated

Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease cGVHD

United States, Japan, France, Belgium
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome

Japan, Turkey
Kyowa Kirin Co., Ltd.

Completed

Open Label Extension Study of AMG 531 in Japanese Subjects With ITP

Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Japan
Sanofi

Recruiting

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (MAYARI)

Thrombotic Thrombocytopenic Purpura

Italy, Belgium, France, Greece, United States, Austria, Canada, Czechia, Germany, Japan, Netherlands, Spain, United Kingdom
Alexion Pharmaceuticals, Inc.

Recruiting

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

Thrombotic Microangiopathy

United States, Italy, Spain, Korea, Republic of, United Kingdom, Belgium, Netherlands, Germany, Japan, Greece, Brazil, Israel, France, China, Sweden, Australia, Canada, Poland
Eli Lilly and Company

Terminated

A Study of LY3435151 in Participants With Solid Tumors

Hepatocellular Carcinoma | Solid Tumor | Gastric Adenocarcinoma | Leiomyosarcoma | Head and Neck Squamous Cell Carcinoma | Cervical Carcinoma | Triple-negative Breast Cancer | Undifferentiated Pleomorphic Sarcoma | High Grade Serous Ovarian Carcinoma

United States, Japan
Alexion Pharmaceuticals, Inc.

Terminated

Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger

Thrombotic Microangiopathy

United States, Belgium, France, Italy, Japan, Spain, Taiwan, United Kingdom, Canada, Korea, Republic of, Netherlands
CSL Behring

Recruiting

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE)

Acute-graft-versus-host Disease

United States, Korea, Republic of, Spain, Australia, Germany, Italy, Turkey, Japan
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) (iNTEGRATE)

Chronic Graft Versus Host Disease

United States, Australia, Austria, Canada, China, Croatia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Singapore, Spain, Taiwan

Clinical Trials on Thrombosis, Venous in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations